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doi:10.1016/j.kjms.2010.05.005Abstract Pheochromocytomas and paragangliomas (extra-adrenal pheochromocytomas) are
catecholamine-secreting tumors. The paraganglioma of the urinary bladder is an uncommon
neoplasm with a higher malignancy rate. Only about 60% of bladder paragangliomas presented
with hematuria, and most of them were microscopic hematuria. Herein, we report two cases
of bladder paraganglioma with bladder bloody tamponade. In Case 1, radical cystectomy and
regional lymphadenectomywereperformed for a hugebladder tumor and left pelvic lymphnodes
metastasized. In Case 2, we chose endoscopic transurethral resection of the bladder tumor.
Literatures since 1989 were also reviewed to illustrate the clinical characteristics and current
treatments.
摘要 嗜鉻細胞瘤及非腎上腺之副節細胞瘤為兒茶酚胺分泌腫瘤。膀胱副節細胞瘤不但少見且有
較高的惡性比率。根據統計，約只有60%的膀胱副節細胞瘤病人有血尿表現，而其中大多為肉眼t of Urology, Kaohsiung Medical University, Kaohsiung, Taiwan, No. 100, Tzyou 1st Road, Kaohsiung
tw (W.-J. Wu).
vier Taiwan LLC. All rights reserved.
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the bladder; (B) the enhanced tum
(3.27 3 cm) in the urinary bladder
tumor with muscle-level invasion.不可見之血尿。在此提出兩位以嚴重出血性膀胱填塞為表現之膀胱副節細胞瘤病人。分別以根除
性膀胱全切除與內視鏡經尿道膀胱腫瘤刮除手術作為治療方式。我們同時分析自1989年以來所有
膀胱副節細胞瘤的病例系列報告，並回顧針對此特殊疾病的臨床診斷及治療方式。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Pheochromocytomas are catecholamine-secreting neo-
plasms, which develop from the cells of the chromaffin
tissues that are derived from the ectodermic neural system
and mostly situated within the adrenal medulla. Only about
10% of pheochromocytomas are extra-adrenal tumors,
known as paragangliomas. Paragangliomas of the urinary
bladder are an extremely rare entity with similar clinical
symptoms of pheochromocytomas and another special
syndrome of catecholamine releasing during micturition,
“micturition attack.” Microscopic hematuria is common,
but only two cases of bladder paragangliomas with profuse
gross hematuria had been reported since 1989 [1]. We,
herein, reported two cases of bladder paragangliomas withi-nodular soft tissue mass (9.1
or with multiple neovasculaity
arising from the dome area wibladder bloody tamponade. Literature of paraganglioma of
the urinary bladder was also reviewed to illustrate the
spectrum of clinical, radiological, and histological charac-
teristics, and current treatment.
Case presentation
A 23-year-old man presented with gross hematuria and
dysuria. Tracing back his medical history, it was found that
he had suffered from intermittent headache and high blood
pressure for 2 years, especially during micturition and stool
passage. Twenty-four-hour urinary vanylmandelic acid was
elevated to 37.64 mg/d. Computed tomography (CT)
revealed a huge mass with heterogeneous enhancement and
central necrosis, arising from the bladder (Fig. 1A and 1B).8.4 cm in diameter) arising from the base and posterior wall of
and central necrosis. Case 2: (C) a contrast-enhanced mass
th bladder bloody tamponade; (D) the sagittal view shows the
Figure 2. (A) The macroscopic appearance of paraganglioma of the urinary bladder (Case 1) is shown. (B) The tumor cells, from
bladder tumor and the lymph node metastasis, are round with acidophilic granular cytoplasm and ovoid nuclei with fine granular
chromatin. They are arranged in discrete nests (the zellballen pattern) separated by a prominent vascular network (hematoxylin-
eosin, reduced from 400). (C) Immunohistochemistry demonstrates positive staining for chromogranin. (D) Immunohistochemistry
demonstrates negative staining for cytokeratin. It has been used for differentiating the diagnosis from transitional cell carcinoma.
All specimens are from Case.
Table 1 Results of univariate analysis of the association between variables and ED
Case 1 Case 2
Age (yr) 23 47
Sex Male Female
Chief complaint Gross hematuria, blood cloterelated acute
urinary retention, intermittent headache
Urine VMA (mg/d) 37.64 N/A
Urine cytology No malignant cells No malignant cells
Familial genetic syndrome No No
Bladder lesion
Size (cm) 9.1 3.27
Location Posterior wall and base Dome area
Enhancement during arterial phase Yes No
Necrosis Yes No
Hemorrhage with bladder tamponade Yes Yes
Distal metastasis No No
Lymph node adenopathy Yes No
Surgical procedure Radical cystectomyþ pelvic
lymph node dissection
Transurethral resection
of bladder tumor
Tumor stage T3N2M0 T2aN0M0
Immunohistochemistry
Chromogranin Positive Positive
Cytokeratin Negative Negative
Zellballen pattern Yes Yes
Rec. or meta. at F/U (mo)a No (13) No (21)
Status Alive Alive
a Blood pressure and urinary VMA returned to normal during follow-up in both cases.
F/UZ follow-up; Meta.Zmetastasis; N/AZ not available; Rec.Z recurrence; VMAZ vanylmandelic acid.
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Table 2 Case series of bladder paragangliomas since 1989
Patients
no.
Male/female
(age range)
Cate.-secreting
symptoms (þ/)
Micturition
attack (þ/)
Hematuria
(þ/)
Tumor size,
range (cm)
Surgery
(open/
TUR)
Chromogranin
(þ//NA)
Rec. or meta.
at F/U (þ//NA)
(mo)
Status
(ANED/
DOD/NA)
Chen et al., 1911 7 3/4 (21e61) 2/5 2/5 7/0a 1.7e5 7/0 7/0/0 0/6/1 (NAe180) 6/0/1
Punekar et al., 1989 2 1/1 (12e40) 1/1 1/1 1/1a 5e7 2/0 0/0/2 0/2/0 (48e54) 2/0/0
Grignon et al., 1991 3 1/2 (19e45) 1/2 1/2 3/0 0.5e2.5 3/0 3/0/0 1/2/0 (9e84) 3/0/0
Salo et al., 1989 2 0/2 (61e84) 1/1 0/2 1/1 2e3 1/1 2/0/0 0/1/1 (2e84) 1/0/1
Liu et al., 2007 6 1/5 (19e53) 4/2 3/3 3/3 NA 6/0 0/0/6 0/5/1 (NA) 5/0/1
Kato et al., 1999 3 2/1 (13e35) 2/1 1/2 2/1 2e4.5 3/0 3/0/0 1/1/1 (48e396) 1/1/1
Thrasher et al., 1993 2 1/1 (30e77) 2/0 2/0 1/1 NAe2.3 2/0 1/0/1 0/2/0 (36e60) 2/0/0
Cheng et al., 2000 16 4/12 (16e74) 8/4b 1/11b 4/8b NA 9/7 16/0/0 3/11/2 (NAe16.4) 8/2/6
Siatelis et al., 2008 2 0/2 (56e73) 0/2 0/2 2/0 3.2e3.4 2/0 2/0/0 0/2/0 (12e108) 2/0/0
Safwat et al., 2007 3 1/2 (11e35) 2/1 2/1 1/2 NA 3/0 0/0/3 0/3/0 (NA) 3/0/0
Ali-el-D et al., 2002 3 0/3 (23e50) 1/2 1/2 3/0 NA 3/0 3/0/0 0/3/0 (40e50) 3/0/0
Karpman et al., 2000 2 0/2 (46e52) 1/1 0/2 1/1 NAe1.2 0/2 2/0/0 0/1/1 (NA) 0/0/2
Our report 2 1/1 (23e47) 2/0 2/0 2/0c 3.27e9.1 1/1 2/0/0 1/1/0 (13e21) 1/0/1
Total 53 15/38 (11e84) 27/22b 16/33b 31/18b NA 42/11 41/0/12 6/40/7 (NA) 37/3/13
a Both had a case performed emergent operation because of massive bleeding
b Four cases were NA
c Both cases presented bladder tamponade with blood clot.
ANEDZ alive with no evidence of disease; Cate.Z catecholamine; DODZ dead of disease; F/UZ follow-up; Meta.Zmetastasis; NAZ not available; Rec.Z recurrence;
TURZ transurethral resection.
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112 C.-C. Tsai et al.Left iliac lymphadenopathy was also demonstrated
(maximum size, 5 cm). Gradually difficult urinary voiding
was complained of, and cystoscopy showed bladder
bloody tamponade. Because of hypertensive crises (blood
pressure, 202/126 mmHg), the transurethral resection (TUR)
of the mass was abandoned immediately. The specimen
showed “zellballen”-pattern neoplastic cells positive for
chromogranin and synaptophysin (Fig. 2) and was confirmed
as a paraganglioma. After alpha-/beta-adrenergic blocker
used for 2 weeks, this patient was subjected to radical
cystectomy, ileal conduit reconstruction, and pelvic lym-
phadenectomy. Histopathological examination showed
malignant paraganglioma of urinary bladder with pelvic
lymphatic metastasis. Follow-up CT and positron emission
tomography did not show recurrence or metastasis.
Another 47-year-old woman who had a history of inter-
mittent headache during urinary voiding came to our
institution with acute urinary retention. CT showed a well-
enhanced tumor at the dome area of urinary bladder with
bladder bloody tamponade (Fig. 1C and 1D). After the blood
clots were evacuated by cystoscopy, a submucosal bladder
tumor with ulcerated mucosa and bleeding point in the
margin was noted. Because of the visualization of submu-
cosal tumor, radical TUR was arranged for definitive diag-
nosis and staging. During the manipulation, the patient’s
blood pressure shot up to 180/120 mmHg and dropped to
80/50 mmHg after complete excision of the tumor. The
pathological diagnosis was bladder paraganglioma with
immunohistochemical analysis confirmation. Because
tumor margin was free, this patient opted for active
surveillance over the partial cystectomy. She remains
disease free according to follow-up by cystoscopy and
Iodine131 metaiodobenzylguanidine (I131-MIBG) scanning.
Table 1 summarizes the patient characteristics.
Discussion
Bladder paragangliomas are rare and arise from the chro-
maffin cells in the detrusor muscle. They account for 0.06%
of all bladder tumors and less than 1% of all catecholamine-
secreting neoplasms [1]. Although most of the para-
gangliomas are sporadic, a growing percentage of cases are
found to be part of a familial genetic syndrome [2].
Furthermore, in certain familial syndromes, the rate of
malignancy in paragangliomas can be as high as 50%, which
is more than the potential of classic pheochromocytomas
(about 10%). Recent studies suggest that genetic testing
should be offered to patients diagnosed with para-
ganglioma, particularly in young patients, or in those who
have multiple tumors or a family history of malignancy [3].
Clinical symptoms of functional bladder paragangliomas
are similar to adrenal pheochromocytomas. Another special
syndrome, called “micturition attack,” occurs continuously
or intermittently in 50% of patients with paragangliomas of
urinary bladder [4]. We reviewed a case series of bladder
paragangliomas since 1989 (Table 2) and found that about
half the cases (48.4%) were associated with “micturition
attack” syndrome. About 60% of bladder paragangliomas
present hematuria [1]. Fifty-three cases were included in
our review, and most of them had painless microscopic
hematuria or clear urine in urinalysis. However, still a fewcases, similar to those in our report, developed critical
bleeding and needed surgical management.
Compared with the typical pheochromocytomas, the
bladder paragangliomas predominantly excrete more
norepinephrine because of lack of converting enzyme. In
light of this situation, the test for norepinephrine before
and after 3 hours of urination is valuable for the diagnosis
[1]. Furthermore, bladder paragangliomas are usually
submucosal homogeneous masses with continuous mucosa
and abundant perfusion. Sometimes, central necrosis or
hemorrhage may result in cystic lesions. Magnetic reso-
nance imaging is superior to CT for the demonstration of
the submucosal tumor and has a higher sensitivity (88%).
Bladder paragangliomas are typically of low signal intensity
on T1-weighted images and moderately high signal intensity
on T2-weighted images. Ring calcification around the
circumference of the mass is another highly suggestive
character. I131-MIBG resembles norepinephrine and can be
taken up by the catecholamine-secreting neoplasms. So
I131-MIBG scanning has a high specificity for localized
pheochromocytoma, especially in the extra-adrenal para-
gangliomas. Positron emission tomography may be superior
in identifying metastatic lymph nodes [4]. Cystoscopy is
another important apparatus in locating the tumor and in
qualitative diagnosis. Tumor irritated by water or tran-
surethral biopsy may cause the release of catecholamines
and induce the “tumor irritation syndrome,” which is also
determinative of the diagnosis. More and more studies
disagree on TUR biopsy for paragangliomas of the urinary
bladder because of its poor sensitivity, easy bleeding, and
relative hypertensive crisis [5].
In microscopic examination, the paragangliomas present
the characteristic “zellballen” pattern (nesting pattern of
round cells into balls) of growth and the high immunoreac-
tivity for neuroendocrine markers (such as chromogranin).
Malignancy is essentially determined by the presence of local
invasionordistalmetastasis (suchas tobones, lungs, liver, and
lymph nodes) [2,6]. Unfortunately, there are no definitive
histological criteria, immunohistochemical markers, molec-
ular features,orclinical characters todetermine itsmalignant
potency at the time of diagnosis. Some studies [2,3,7] showed
that extra-adrenal paragangliomas have a higher incidence of
distal metastasis and local recurrence than adrenal pheo-
chromocytomas. Through literature review, we also found
the same deviation with a malignancy rate of 13%. Although
the clinical prognosis of malignant patients is equivocal,
overall 5-year survival rate for patients with metastatic
pheochromocytoma or paraganglioma is about less than 50%,
and both morbidity and mortality increase with higher circu-
lating catecholamine level [3].
Although some patients were reported to receive TUR
procedure, most cases of bladder paragangliomas were
suggested for partial or radical cystectomy, which is 79%
cases in our view. Suggestion for open surgery treatment is
given for the following four reasons: (1) TUR can irrigate
the tumors; (2) a submucosal location is difficult to control
the extent of TUR; (3) the tumor is often recurrent if
resected incompletely; and (4) the prevalence of malig-
nancy is higher. Laparoscopic procedure is another choice
but may irritate the tumor by air pressure. It is essential to
continue invasive hemodynamic monitoring as the changes
in vascular tone may fluctuate rapidly in the early
Bladder paraganglioma with bloody tamponade 113postoperative period. Repeatedly close follow-up with
indefinite annual biochemical screening is recommended
for the reason that tumor recurrence may occur months or
years after the initial operation. If complete radical
resection is not available, arterial embolization, cryoa-
blation, chemotherapy, and MIBG radiation therapy can be
considered [8]. However, the rarity of this kind of tumor has
limited the proper development of these therapies. Meta-
static pheochromocytomas have been treated with
a variety of chemotherapeutic agents, including cyclo-
phosphamide, vincristine, and dacarbazine. Huang et al. [9]
showed a tumor response rate of 55% and a biochemical
response rate of 72%. Notwithstanding, the long-term effi-
cacy and the most effective agents remain to be seen.
Radiotherapy is considered only in the palliative treatment
of painful bone metastasis or spinal cord compression.
Retrospective review of the 116 published cases of malig-
nant tumors treated with radiation therapy showed 76%
rate of symptomatic improvement [10]. Further studies in
this regard and long-term follow-up of patients receiving
surgery and other therapies are necessary to establish
a standard for treatment and follow-up.
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